Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne
Good news from Italfarmaco! As discussed on our webinar last week, an Independent Data Monitoring Committee (IDMC) has recommended the continuation of their Phase 3 Givinostat trial, determining that the trial is not futile. They…Learn More